Declan Doogan - 09 Jan 2026 Form 4 Insider Report for TENAX THERAPEUTICS, INC. (TENX)

Role
Director
Signature
/s/ S. Halle Vakani, as Attorney-in-Fact
Issuer symbol
TENX
Transactions as of
09 Jan 2026
Net transactions value
$0
Form type
4
Filing time
13 Jan 2026, 20:03:44 UTC
Previous filing
03 Jul 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Doogan Declan Director 101 GLEN LENNOX DRIVE SUITE 300, CHAPEL HILL /s/ S. Halle Vakani, as Attorney-in-Fact 13 Jan 2026 0001704234

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding TENX Common Stock 2,274 09 Jan 2026 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TENX Stock Option (right to buy) Award $0 +30,000 $0.000000 30,000 09 Jan 2026 Common Stock 30,000 $13.30 Direct
holding TENX Stock Option (right to buy) 4 09 Jan 2026 Common Stock 4 $3200.00 Direct
holding TENX Stock Option (right to buy) 4 09 Jan 2026 Common Stock 4 $992.00 Direct
holding TENX Stock Option (right to buy) 100,000 09 Jan 2026 Common Stock 100,000 $5.94 Direct
holding TENX Stock Option (right to buy) 80,000 09 Jan 2026 Common Stock 80,000 $5.75 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.